IBRXImmunityBio, Inc.
$10.51+285% 1Y
$10.51
$1.9852 weeks$11.55
IBRX in its own filings
IBRX's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
188
Events found in the filings · across 553 filings · the record starts in 2015
- Hard flags
- 2
Hard flags
- Most recent filing
- Aug 4, 2026
Most recent filing · Form 10-Q
- Record starts
- Jun 10, 2015
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- Restatement admitted (non-reliance)historical
- 2016-03-11
- Change in certifying accountant2 occurrences
- 2025-03-19
- SEC comment-letter activity22 occurrences
- 2024-04-30
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million.Earnings release · press release
- Jul 30, 2026ImmunityBio Receives United Arab Emirates (UAE) Marketing.Regulation FD disclosure · press release
- May 18, 2026On May 14, 2026, ImmunityBio, Inc., a Delaware corporation (“ImmunityBio” or the “Company”), entered into an exclusive development and supply agreement (the “Agreement”) with Japan BCG Laboratory, a Japanese corporation (“JBL”)Material agreement entered · Form 8-K
- May 7, 2026ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue.Earnings release · press release
- Apr 9, 2026ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year.Earnings release · press release
- Apr 6, 2026ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance.Regulation FD disclosure · press release
- Mar 31, 2026Amendment to Revenue Interest Purchase Agreement On March 30, 2026, ImmunityBio, Inc. (the “Company”) entered into a Second Amendment to Revenue Interest Purchase Agreement (the “Amendment”) by and among the Company, the guarantors party thereto, the purchasers party thereto (the “Purchasers”) and Infinity SA LLC, as …Material agreement entered · Form 8-K
- Feb 23, 2026ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded.Earnings release · press release
- Feb 18, 2026On February 18, 2026, ImmunityBio, Inc. (“ImmunityBio” or the “Company”) issued a press release announcing that the Company has received authorization from the European Commission for ANKTIVA ® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, which expands global access of our product to 33 countries.Other event · Form 8-K
- Jan 26, 2026On January 23, 2026, ImmunityBio, Inc. (the “Company”) entered into a letter amendment (the “Convertible Note Amendment”) to that certain convertible Second Amended and Restated Promissory Note, dated December 10, 2024, in an outstanding principal amount of $505.0 million (the “Convertible Promissory Note”), by and …Material agreement entered · Form 8-K
- Jan 15, 2026ImmunityBio Reports Continued Execution and Sales.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks